TY - JOUR
T1 - Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo
AU - Jiang, Zhenqi
AU - Li, Yanying
AU - Wei, Zhenni
AU - Yuan, Bo
AU - Wang, Yinjie
AU - Akakuru, Ozioma Udochukwu
AU - Li, Yong
AU - Li, Juan
AU - Wu, Aiguo
N1 - Publisher Copyright:
© 2020 [The Author/The Authors]
PY - 2021/3
Y1 - 2021/3
N2 - Zeolitic Imidazole Frameworks (ZIFs) are widely applied in nanomedicine for their high drug loading, suitable pore size, pH-responsive drug release, and so on. However, fast drug release during circulation, unexpected toxicity to mice major organs, undesirable long-term accumulation in the lung and even death currently hinder their in vivo biomedical applications. Herein, we report an amorphous ZIF-8 (aZIF-8) with high loading of 5-Fu through pressure-induced amorphization. This nano-system avoids early drug release during circulation and provides tumor microenvironment-responsive drug release with improved in vitro cell viability, and survival rate in in vivo evaluations as compared to ZIF-8. Furthermore, aZIF-8 shows longer blood circulation and lower lung accumulation than ZIF-8 at same injected doses. Less drug release during circulation, longer blood circulation, and better biocompatibility of aZIF-8/5-Fu significantly improves its therapeutic efficacy in ECA-109 tumor-bearing mouse, and result in 100% survival rate over 50 days after treatment. Therefore, aZIF-8 with favorable biocompatibility and long blood circulation is expected to be a promising nano-system for efficacious cancer therapy in vivo.
AB - Zeolitic Imidazole Frameworks (ZIFs) are widely applied in nanomedicine for their high drug loading, suitable pore size, pH-responsive drug release, and so on. However, fast drug release during circulation, unexpected toxicity to mice major organs, undesirable long-term accumulation in the lung and even death currently hinder their in vivo biomedical applications. Herein, we report an amorphous ZIF-8 (aZIF-8) with high loading of 5-Fu through pressure-induced amorphization. This nano-system avoids early drug release during circulation and provides tumor microenvironment-responsive drug release with improved in vitro cell viability, and survival rate in in vivo evaluations as compared to ZIF-8. Furthermore, aZIF-8 shows longer blood circulation and lower lung accumulation than ZIF-8 at same injected doses. Less drug release during circulation, longer blood circulation, and better biocompatibility of aZIF-8/5-Fu significantly improves its therapeutic efficacy in ECA-109 tumor-bearing mouse, and result in 100% survival rate over 50 days after treatment. Therefore, aZIF-8 with favorable biocompatibility and long blood circulation is expected to be a promising nano-system for efficacious cancer therapy in vivo.
KW - Amorphous zeolitic imidazole frameworks
KW - Chemotherapy
KW - Esophageal squamous cell carcinoma
KW - Pressure-induced amorphization
UR - http://www.scopus.com/inward/record.url?scp=85091478779&partnerID=8YFLogxK
U2 - 10.1016/j.bioactmat.2020.08.036
DO - 10.1016/j.bioactmat.2020.08.036
M3 - Article
AN - SCOPUS:85091478779
SN - 2452-199X
VL - 6
SP - 740
EP - 748
JO - Bioactive Materials
JF - Bioactive Materials
IS - 3
ER -